Introduction/Background Borderline tumors are uncommon malignant epithelial ovarian tumors, thus experience in management and outcome is still deficient. In this study we aim to evaluate the oncological and reproductive outcomes in patients with borderline ovarian tumors (BOT) cancer treated with fertility-sparing surgery (FSS).

Methodology Retrospective descriptive cohort study conducted on patients with borderline ovarian tumors (BOT) who underwent surgery between 2019 and 2023 and follow up done over a mean period of 26 months. The oncological outcome is assessed based on estimating recurrence rate. The reproductive outcome is assessed by the menstrual status and the number of pregnancies and term deliveries.

Results A total of 24 patients fulfilled the inclusion criteria. The median age at diagnosis was 21.75 years with a range from 16 to 42, Regarding the histological subtypes, 14 women (58.3%) had serous and 9 (37.5%) had mucinous BOT, while sero-mucinous histology was found in 1 patients (4.1%). The mean follow up was 26 months. During this period four patients (16.67%) experienced recurrence during follow up period, 3 of them was of the SBOT group (one of which was diagnosed at FIGO stage 1A, the second was diagnosed at FIGO 1B stage, while the third one was of stage 2B). the fourth patient was of the MBOT group diagnosed at stage 1A. Of 15 patients desiring pregnancy, 11 patients were successful and resulted in 11 term deliveries; with a percentage of 73.3%, 9 of them were of SBOT, while the last 2 was of the MBOT group.

Conclusion FSS is feasible for young patients who wish to preserve their fertility. Patients initially treated with ovarian cystectomy or unilateral adnexectomy may be managed by close surveillance if post-operative imaging are negative.

Disclosures The authors declare no conflict of interest.

This research received no external funding.